Equities Analysts Offer Predictions for Biohaven Q3 Earnings

Biohaven Ltd. (NYSE:BHVN) – HC Wainwright cut their Q3 2026 EPS estimates for shares of Biohaven in a report released on Wednesday, August 12th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.86) for the quarter, down from their previous forecast of ($0.84). HC Wainwright has a “Neutral” rating and a $10.00 price target on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Biohaven’s Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.44) EPS, FY2027 earnings at ($3.05) EPS, FY2028 earnings at ($2.41) EPS and FY2029 earnings at ($1.41) EPS.

Several other research firms also recently commented on BHVN. Morgan Stanley boosted their price objective on Biohaven from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Bank of America reaffirmed an “underperform” rating and set a $11.00 target price (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a report on Wednesday, May 27th. Wall Street Zen upgraded shares of Biohaven from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Biohaven in a report on Friday, June 26th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $21.75.

Biohaven Trading Up 4.6%

NYSE BHVN opened at $14.31 on Monday. The firm has a market capitalization of $2.16 billion, a PE ratio of -3.08 and a beta of 1.26. The business’s 50-day moving average price is $14.67 and its two-hundred day moving average price is $11.78. The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23. Biohaven has a 12 month low of $7.48 and a 12 month high of $18.57.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15).

Institutional Trading of Biohaven

Hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC increased its position in shares of Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock worth $148,214,000 after purchasing an additional 16,127,247 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Biohaven during the second quarter worth about $196,574,000. Suvretta Capital Management LLC lifted its stake in Biohaven by 83.0% in the fourth quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock valued at $116,140,000 after buying an additional 4,666,666 shares during the last quarter. Stifel Financial Corp raised its position in Biohaven by 50.3% in the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock valued at $112,221,000 after purchasing an additional 3,328,506 shares during the last quarter. Finally, Jupiter Topco LLC purchased a new stake in shares of Biohaven in the second quarter valued at about $127,852,000. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.